A Phase 2 interventional study of Atacicept 75 mg and Atacicept 150 mg in Lupus Erythematosus, Systemic, sponsored by EMD Serono. Terminated at 84 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-21.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany — 3 open to participants now, 4 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Merck KGaA, Darmstadt, Germany.
Among the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, this one is the 7th largest by enrollment, is the only one that started in 2014, is one of 6 in phase 2, and was the 4th registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →3 of the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany are open now, in 12 countries. Recruiting first, the newest first:
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
EMD Serono Research & Development Institute, Inc. · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–75
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 4
First in 2008; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 253 is above the median of 52 across 879 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 280 across the 12 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, double-blind, Phase 2b, long-term extension (LTE) to the ADDRESS II core trial (EMR 700461-023) (NCT01972568), to evaluate long-term safety and tolerability of atacicept in participants with systemic lupus erythematosus (SLE). Participants who completed the 24-week core study ADDRESS II core study (NCT01972568) and thus not met any of the discontinuation criteria were invited to enter this long-term extension (LTE) study NCT02070978.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Atacicept 75 mg
Drug: Atacicept 150 mg
Drug: Atacicept 150 mg
Participants who received atacicept 75 milligram (mg) as once-weekly subcutaneous injection in the core study ADDRESS II continued to receive this dose during this LTE study. Participants in this reporting arm received the medication up to a maximum of 143.7 weeks.
Participants who received placebo in the core study ADDRESS II switched to receive atacicept 150 mg as once-weekly subcutaneous injection for up to a maximum of 97.7 weeks during this LTE study.
Participants who received atacicept 150 mg in core study ADDRESS II continued to receive atacicept 150 mg as once-weekly subcutaneous injection during this LTE study up to a maximum of 97.9 weeks.
Number of Participants With at Least One Serious Adverse Event (SAE) During the Treatment Period
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. Treatment- Emergent adverse events (TEAEs) during the treatment period exclude those ongoing at the time of study entry into 024 LTE Day 1 and exclude the safety follow-up period.
Time frame: Baseline (LTE Day 1) up to maximum treatment duration of 143.7 weeks
Number of Participants Who Prematurely Discontinued the Treatment Due to Adverse Event (AE)
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. TEAEs were defined as events with an onset date on or after the date of first dose of study treatment in the core study and ongoing at the 024 LTE study entry, occurring during the 024 LTE study and the Safety follow-up Period.
Time frame: Baseline (Day 1 of Core study) up to maximum duration of 167.7 weeks
Change From Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Organ Damage Scores
SLICC/ACR score or damage index evaluates cumulative damage in Systemic Lupus Erythematosus (SLE). These changes may or may not be related to SLE. Most items are scored only if they have been present for at least 6 months. Scores range from 0 to 47 points, with higher scores indicating greater cumulative damage. Baseline was defined as Day 1 of Core study.
Time frame: Baseline: Day 1 (Core Study), Day 1 (LTE Study), Week 24, Week 48, Week 72 and Week 96
Change From Baseline in Disease Activity as Measured by British Isles Lupus Assessment Group (BILAG) 2004 Score
BILAG Disease Activity Index evaluates systemic lupus erythematosus (SLE) activity in 8 organ system domains: General, mucocutaneous, neurological, musculoskeletal, cardiorespiratory, vasculitis, renal, and hematologic using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Severe disease activity; BILAG B: moderate disease activity; BILAG C: mild disease; BILAG D: system previously affected but now inactive; BILAG E: system never involved. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). The total BILAG score is the sum of the scores of the 8 domains where A=9, B=3, C=1, D=0, and E=0. The total score ranges from 0 to 72 with a higher score indicating greater lupus activity.
Time frame: Baseline: Core study Screening, LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Change From Baseline in Disease Activity as Measured by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score
SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms). Baseline was defined as core study screening visit.
Time frame: Baseline: Screening Visit (Core Study); LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Change From Baseline in Disease Activity as Measured by SLEDAI-2K Responder Index-50 (SRI-50) Score
SRI-50 index was derived from SLEDAI-2K and could capture 50% or better improvement in each descriptor between any 2 visits in systemic lupus erythematosus (SLE) participants when there was incomplete resolution. The new assigned scores for the descriptors of SRI-50 were derived by dividing the score of each SLEDAI-2K descriptor by 2. SLEDAI-2K was an activity index that measured disease activity and records feature of active lupus as present or not present. SLEDAI-2K used a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present was assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranged from 0 points (no symptoms) to 105 points (presence of all defined symptoms).
Time frame: Baseline: Screening Visit (Core Study); LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Change From Baseline in Disease Activity as Measured by Physician's Global Assessment (PGA) Score
The PGA was used to quantify disease activity and was measured using an anchored visual analog scale (VAS). The participant's current disease activity assessed by investigator in the score range of 0 to 3. Where 0=none; 1=mild; 2=moderate; 3=severe. The assessment made relative not to the participant's most severe state, but the most severe state of systemic lupus erythematosus (SLE) per the investigator's assessment. Baseline was defined as core study screening visit.
Time frame: Baseline: Screening Visit (Core Study); LTE Day1, Week 24, Week 48, Week 72 and Week 96
Number of Participants Who Achieved SLE Responder Index (SRI-4) Response (a Disease Activity Composite Index)
SRI-4 response was defined as greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline Physician's Global Assessment of Disease Activity (PGA). SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms).
Time frame: Baseline: Core study Screening; LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Number of Participants Who Achieved BILAG-based Combined Lupus Assessment (BICLA) Response (a Disease Activity Composite Index)
The BICLA response was defined as BILAG-2004 improvement (all screening visit BILAG A improving to B/C/D, all screening visit BILAG B to C/D, and less than or equal to (\<=1) new BILAG B and no new BILAG A); no deterioration in SLEDAI total score; PGA increase by less than (\<) 0 percentage (%) (defined as less then (\<)0.3 point increase for the statistical analyses) and no non-permitted medication/treatment. Baseline was defined as core study screening visit.
Time frame: Baseline: Core study Screening; LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Percent Change From Baseline in Prednisone-equivalent Corticosteroid Dose
Time frame: Baseline: Screening Visit (Core Study); LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Change From Baseline in the Short-Form (SF-36) Health Survey Physical Component Score and Mental Component Score
The 36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) is based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0-100 (100=highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100=highest level of physical functioning).
Time frame: Baseline (Core Study Day 1); LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Change From Baseline in Lupus Quality of Life (LupusQoL) Questionnaire Score
The LupusQoL was a lupus-specific health related QoL (HRQoL) questionnaire consisting of 34 items grouped in 8 domains: physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Participants indicate their responses on a 5-point Likert response format, where 4 = never, 3 = occasionally, 2 = a good bit of the time, 1 = most of the time, and 0 = all of the time. Summary scores can be calculated for all 8 domains. A LupusQoL score for each domain was reported on a 0 to 100 scale, with greater values indicating better HRQoL. Baseline was defined as Day 1 of core study.
Time frame: Baseline (Core Study Day 1); LTE Day 1, Week 24, Week 48, Week 72, and Week 96
Number of Participants With Patient Global Impression of Change (PGIC)
The PGIC is self-rated scale that asks the participant to describe the change in activity limitations, symptoms, emotions, and overall Quality of life (QoL) related to the participant's painful condition on the following scale: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) and 7 (very much worse). Number of participants in the PGIC categories of very much improved (1) and much improved (2) are reported.
Time frame: Baseline (Core Study Day 1); LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Change From Baseline in EuroQoL 5 Dimension Instrument (EQ-5D) Score
EQ-5D questionnaire comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels; 1=no problem, 2=moderate problems, 3=extreme problems. This part, called the EQ-5D descriptive system, provides a 5-dimensional description of health status. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. Baseline was defined as Day 1 of Core study.
Time frame: Baseline: Day 1 (Core Study), LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) Scores
EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Baseline defined as Day 1 of core study.
Time frame: Baseline: Day 1 (Core Study), LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status.
Time frame: Baseline: Day 1 (Core study); LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Number of Participants With at Least One Adverse Event
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. Treatment-Emergent adverse events (TEAEs) are defined as events with an onset date on or after the date of first dose of study treatment in the core study and ongoing at LTE study entry, or occurring during LTE study.
Time frame: Baseline (Day 1 of Core study) up to maximum duration of 167.7 weeks
Number of Participants With Columbia-Suicide Severity Rating Scale (C-SSRS) Score
The C-SSRS assesses the suicidal behavior and suicidal ideation in participants. Occurrence of suicidal behavior after study entry is defined as having answered "yes" to a least 1 of the 4 suicidal behavior subcategories (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Occurrence of suicidal ideation is defined as having answered "yes" to at least 1 of the suicidal ideation sub-categories (1) wish to be dead, (2) nonspecific active suicidal thoughts, (3) active suicidal ideation with any methods (no plan) without intent to act, (4) active suicidal ideation with some intent to act (without specific plan), and (5) active suicidal ideation with specific plan and intent).
Time frame: LTE Day 1, Week 24, Week 48, Week 72 and Week 98
Participants who completed 24-week of the ADDRESS II core study (NCT01972568) and didn't meet any discontinuation criteria were enrolled in this long-term extension (LTE) study NCT02070978. The study was conducted at 81 sites in 17 countries in Asia, Europe, North America, Central America, and South America.
| Milestone | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Started | 83 | 82 | 88 |
| Completed | 36 | 29 | 35 |
| Not completed | 47 | 53 | 53 |
| Withdrew: Adverse event | 6 | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 3 | 4 |
| Withdrew: Withdrawal by subject | 3 | 5 | 3 |
| Withdrew: Protocol violation | 1 | 0 | 3 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 2 |
| Withdrew: Un-specified | 3 | 2 | 2 |
| Withdrew: Terminated by sponsor | 33 | 40 | 39 |
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. Treatment- Emergent adverse events (TEAEs) during the treatment period exclude those ongoing at the time of study entry into 024 LTE Day 1 and exclude the safety follow-up period.
| Participants | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Number of Participants With at Least One Serious Adverse Event (SAE) During the Treatment Period | 13 | 10 | 9 |
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. TEAEs were defined as events with an onset date on or after the date of first dose of study treatment in the core study and ongoing at the 024 LTE study entry, occurring during the 024 LTE study and the Safety follow-up Period.
| Participants | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Number of Participants Who Prematurely Discontinued the Treatment Due to Adverse Event (AE) | 9 | 4 | 5 |
SLICC/ACR score or damage index evaluates cumulative damage in Systemic Lupus Erythematosus (SLE). These changes may or may not be related to SLE. Most items are scored only if they have been present for at least 6 months. Scores range from 0 to 47 points, with higher scores indicating greater cumulative damage. Baseline was defined as Day 1 of Core study.
| Units on a scale | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Baseline; Day 1 (Core Study) | 1 ± 1.0 | 1 ± 1.2 | 0 ± 0.8 |
| Change at LTE Day 1 | 0 ± 0.0 | 0 ± 0.1 | 0 ± 0.0 |
| Change at LTE Week 24 | 0 ± 0.1 | 0 ± 0.1 | 0 ± 0.2 |
| Change at LTE Week 48 | 0 ± 0.2 | 0 ± 0.2 | 0 ± 0.3 |
| Change at LTE Week 72 | 0 ± 0.3 | 0 ± 0.3 | 0 ± 0.2 |
| Change at LTE Week 96 | 0 ± 0.3 | 0 ± 0.3 | 0 ± 0.0 |
BILAG Disease Activity Index evaluates systemic lupus erythematosus (SLE) activity in 8 organ system domains: General, mucocutaneous, neurological, musculoskeletal, cardiorespiratory, vasculitis, renal, and hematologic using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Severe disease activity; BILAG B: moderate disease activity; BILAG C: mild disease; BILAG D: system previously affected but now inactive; BILAG E: system never involved. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). The total BILAG score is the sum of the scores of the 8 domains where A=9, B=3, C=1, D=0, and E=0. The total score ranges from 0 to 72 with a higher score indicating greater lupus activity.
| Units on a scale | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Baseline: Core study Screening | 15 ± 7.1 | 14 ± 7.2 | 16 ± 6.1 |
| Change at LTE Day 1 | -8 ± 6.9 | -9 ± 7.2 | -10 ± 6.8 |
| Change at LTE Week 24 | -8 ± 8.3 | -10 ± 7.5 | -12 ± 7.2 |
| Change at LTE Week 48 | -9 ± 7.7 | -8 ± 7.5 | -11 ± 7.4 |
| Change at LTE Week 72 | -9 ± 7.9 | -10 ± 6.2 | -11 ± 8.2 |
| Change at LTE Week 96 | -14 ± 12.9 | -8 ± 6.3 | -12 ± 6.8 |
SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms). Baseline was defined as core study screening visit.
| Units on a scale | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Baseline: Screening Visit (Core Study) | 10 ± 2.9 | 10 ± 3.4 | 10 ± 3.0 |
| Change at LTE Day 1 | -4 ± 4.1 | -5 ± 4.5 | -5 ± 3.9 |
| Change at LTE Week 24 | -5 ± 4.3 | -6 ± 4.1 | -6 ± 3.9 |
| Change at LTE Week 48 | -6 ± 3.4 | -6 ± 4.6 | -7 ± 4.3 |
| Change at LTE Week 72 | -5 ± 3.8 | -6 ± 3.7 | -7 ± 3.9 |
| Change at LTE Week 96 | -7 ± 5.0 | -6 ± 4.9 | -8 ± 2.7 |
SRI-50 index was derived from SLEDAI-2K and could capture 50% or better improvement in each descriptor between any 2 visits in systemic lupus erythematosus (SLE) participants when there was incomplete resolution. The new assigned scores for the descriptors of SRI-50 were derived by dividing the score of each SLEDAI-2K descriptor by 2. SLEDAI-2K was an activity index that measured disease activity and records feature of active lupus as present or not present. SLEDAI-2K used a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present was assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranged from 0 points (no symptoms) to 105 points (presence of all defined symptoms).
No measurements were reported for this outcome.
The PGA was used to quantify disease activity and was measured using an anchored visual analog scale (VAS). The participant's current disease activity assessed by investigator in the score range of 0 to 3. Where 0=none; 1=mild; 2=moderate; 3=severe. The assessment made relative not to the participant's most severe state, but the most severe state of systemic lupus erythematosus (SLE) per the investigator's assessment. Baseline was defined as core study screening visit.
| Units on a scale | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Baseline: Screening Visit (Core Study) | 1.56 ± 0.424 | 1.46 ± 0.509 | 1.47 ± 0.460 |
| Change at LTE Day 1 | -0.76 ± 0.559 | -0.77 ± 0.559 | -0.77 ± 0.614 |
| Change at LTE Week 24 | -0.91 ± 0.620 | -0.85 ± 0.555 | -0.94 ± 0.547 |
| Change at LTE Week 48 | -1.01 ± 0.647 | -0.86 ± 0.522 | -0.99 ± 0.557 |
| Change at LTE Week 72 | -0.90 ± 0.758 | -0.84 ± 0.503 | -1.03 ± 0.580 |
| Change at LTE Week 96 | -1.17 ± 0.518 | -0.72 ± 0.579 | -1.21 ± 0.411 |
SRI-4 response was defined as greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline Physician's Global Assessment of Disease Activity (PGA). SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms).
| Participants | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| LTE Day 1 | 42 | 52 | 57 |
| LTE Week 24 | 43 | 57 | 60 |
| LTE Week 48 | 44 | 46 | 51 |
| LTE Week 72 | 21 | 23 | 23 |
| LTE Week 96 | 6 | 9 | 12 |
The BICLA response was defined as BILAG-2004 improvement (all screening visit BILAG A improving to B/C/D, all screening visit BILAG B to C/D, and less than or equal to (\<=1) new BILAG B and no new BILAG A); no deterioration in SLEDAI total score; PGA increase by less than (\<) 0 percentage (%) (defined as less then (\<)0.3 point increase for the statistical analyses) and no non-permitted medication/treatment. Baseline was defined as core study screening visit.
| Participants | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| LTE Day 1 | 43 | 43 | 50 |
| LTE Week 24 | 40 | 45 | 53 |
| LTE Week 48 | 35 | 34 | 43 |
| LTE Week 72 | 16 | 17 | 21 |
| LTE Week 96 | 4 | 7 | 9 |
| Percent change | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Percent Change at LTE Day 1 | -11.04 ± 31.139 | -5.25 ± 55.697 | -11.54 ± 26.117 |
| Percent Change at LTE Week 24 | -11.89 ± 41.411 | -4.79 ± 59.371 | -1.21 ± 94.677 |
| Percent Change at LTE Week 48 | -9.19 ± 54.364 | -6.01 ± 45.605 | -17.97 ± 37.040 |
| Percent Change at LTE Week 72 | -19.32 ± 38.157 | -8.69 ± 28.112 | -22.34 ± 36.058 |
| Percent Change at LTE Week 96 | -36.67 ± 58.146 | -12.40 ± 73.793 | -28.57 ± 43.080 |
The 36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) is based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0-100 (100=highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100=highest level of physical functioning).
| Units on a scale | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| PCS: Baseline (Core Study Day 1) | 37.7 ± 9.20 | 37.8 ± 10.56 | 38.8 ± 9.27 |
| PCS: Change at LTE Day 1 | 4.8 ± 10.00 | 4.8 ± 8.30 | 4.0 ± 7.46 |
| PCS: Change at LTE Week 24 | 5.3 ± 8.62 | 5.1 ± 8.78 | 5.9 ± 7.74 |
| PCS: Change at LTE Week 48 | 6.4 ± 9.56 | 6.2 ± 9.67 | 4.6 ± 8.23 |
| PCS: Change at LTE Week 72 | 5.8 ± 8.61 | 3.4 ± 7.37 | 6.7 ± 5.33 |
| PCS: Change at LTE Week 96 | 13.0 ± 9.51 | 3.1 ± 9.29 | 8.9 ± 6.08 |
| MCS: Baseline (Core Study Day 1) | 41.3 ± 10.70 | 43.3 ± 12.09 | 43.2 ± 10.81 |
| MCS: Change at LTE Day 1 | 2.1 ± 11.38 | 2.2 ± 12.62 | 1.9 ± 9.30 |
| MCS: Change at LTE Week 24 | 4.4 ± 10.43 | 3.0 ± 11.75 | 2.0 ± 10.26 |
| MCS: Change at LTE Week 48 | 3.3 ± 11.72 | 2.8 ± 13.19 | 3.5 ± 11.39 |
| MCS Change at LTE Week 72 | 3.8 ± 10.96 | 1.1 ± 11.74 | 1.5 ± 13.64 |
| MCS: Change at LTE Week 96 | 10.3 ± 15.86 | 0.6 ± 9.03 | 3.2 ± 12.20 |
The LupusQoL was a lupus-specific health related QoL (HRQoL) questionnaire consisting of 34 items grouped in 8 domains: physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Participants indicate their responses on a 5-point Likert response format, where 4 = never, 3 = occasionally, 2 = a good bit of the time, 1 = most of the time, and 0 = all of the time. Summary scores can be calculated for all 8 domains. A LupusQoL score for each domain was reported on a 0 to 100 scale, with greater values indicating better HRQoL. Baseline was defined as Day 1 of core study.
| Units on a scale | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Physical Health: Baseline (Core study Day 1) | 60.2 ± 23.08 | 62.0 ± 27.17 | 61.3 ± 27.87 |
| Physical Health: Change at LTE Day 1 | 8.8 ± 21.86 | 7.5 ± 17.37 | 8.2 ± 16.40 |
| Physical Health: Change at LTE Week 24 | 10.4 ± 21.27 | 10.8 ± 18.86 | 10.9 ± 18.46 |
| Physical Health: Change at LTE Week 48 | 9.3 ± 22.23 | 11.2 ± 24.80 | 12.8 ± 20.30 |
| Physical Health: Change at LTE Week 72 | 8.0 ± 19.42 | 5.9 ± 17.61 | 11.9 ± 20.02 |
| Physical Health: Change at LTE Week 96 | 25.0 ± 21.46 | 12.9 ± 17.97 | 14.4 ± 10.33 |
| Pain: Baseline (Core study Day 1) | 58.7 ± 26.77 | 61.2 ± 30.27 | 57.7 ± 31.52 |
| Pain: Change at LTE Day 1 | 11.8 ± 24.86 | 11.0 ± 23.93 | 13.4 ± 21.78 |
| Pain: Change at LTE Week 24 | 14.4 ± 26.21 | 11.9 ± 23.38 | 16.4 ± 24.10 |
| Pain: Change at LTE Week 48 | 12.8 ± 27.76 | 14.0 ± 29.64 | 17.3 ± 24.67 |
| Pain: Change at LTE Week 72 | 16.7 ± 26.73 | 10.3 ± 18.91 | 17.2 ± 26.63 |
| Pain: Change at LTE Week 96 | 41.7 ± 30.21 | 11.9 ± 23.73 | 17.9 ± 23.78 |
| Planning: Baseline (Core study Day 1) | 65.6 ± 27.52 | 68.3 ± 30.81 | 64.6 ± 33.26 |
| Planning: Change at LTE Day 1 | 8.4 ± 25.60 | 1.5 ± 22.79 | 7.5 ± 23.08 |
| Planning: Change at LTE Week 24 | 11.2 ± 27.34 | 7.0 ± 24.16 | 8.4 ± 25.29 |
| Planning: Change at LTE Week 48 | 14.5 ± 29.27 | 6.5 ± 26.88 | 10.9 ± 26.16 |
| Planning: Change at LTE Week 72 | 10.3 ± 22.23 | 0.0 ± 28.37 | 15.5 ± 30.52 |
| Planning: Change at LTE Week 96 | 19.8 ± 36.98 | 3.0 ± 24.59 | 21.8 ± 26.03 |
| Intimate Relationship: Baseline (Core study Day 1) | 67.2 ± 30.99 | 60.6 ± 34.17 | 62.1 ± 31.62 |
| Intimate Relationship: Change at LTE Day 1 | 3.9 ± 26.95 | 0.2 ± 27.77 | -1.6 ± 23.94 |
| Intimate Relationship: Change at LTE Week 24 | 3.6 ± 26.29 | 7.1 ± 24.50 | 6.3 ± 25.67 |
| Intimate Relationship: Change at LTE Week 48 | 2.3 ± 29.19 | 5.7 ± 33.02 | 8.4 ± 30.58 |
| Intimate Relationship: Change at LTE Week 72 | -6.3 ± 20.67 | -2.8 ± 29.89 | 5.2 ± 32.95 |
| Intimate Relationship: Change at LTE Week 96 | 12.5 ± 15.31 | 2.9 ± 16.26 | -14.3 ± 39.81 |
| Burden to Others: Baseline (Core study Day 1) | 49.0 ± 31.22 | 48.5 ± 32.34 | 47.3 ± 32.97 |
| Burden to Others: Change at LTE Day 1 | 13.4 ± 26.31 | 14.7 ± 25.83 | 12.5 ± 25.36 |
| Burden to Others: Change at LTE Week 24 | 13.1 ± 26.08 | 16.8 ± 27.35 | 15.7 ± 27.73 |
| Burden to Others: Change at LTE Week 48 | 13.4 ± 25.69 | 18.3 ± 30.36 | 17.9 ± 28.73 |
| Burden to Others: Change at Week 72 | 12.1 ± 21.89 | 14.4 ± 32.23 | 22.1 ± 31.68 |
| Burden to Others: Change at LTE Week 96 | 17.7 ± 32.56 | 20.2 ± 33.29 | 30.1 ± 37.51 |
| Emotional Health: Baseline (Core study Day 1) | 64.1 ± 23.43 | 68.3 ± 25.86 | 67.6 ± 27.10 |
| Emotional Health: Change at LTE Day 1 | 7.9 ± 19.73 | 6.0 ± 20.08 | 7.0 ± 21.21 |
| Emotional Health: Change at LTE Week 24 | 11.2 ± 20.67 | 6.7 ± 21.87 | 7.9 ± 20.68 |
| Emotional Health: Change at LTE Week 48 | 14.2 ± 21.91 | 9.3 ± 25.66 | 8.0 ± 21.73 |
| Emotional Health: Change at LTE Week 72 | 10.1 ± 20.49 | 3.2 ± 17.50 | 11.5 ± 26.30 |
| Emotional Health: Change at LTE Week 96 | 22.4 ± 26.16 | 6.8 ± 12.40 | 16.3 ± 22.08 |
| Body Image: Baseline (Core study Day 1) | 63.8 ± 27.82 | 61.9 ± 31.45 | 64.4 ± 30.51 |
| Body Image: Change at LTE Day 1 | 12.9 ± 24.47 | 6.2 ± 20.69 | 4.7 ± 25.29 |
| Body Image: Change at LTE Week 24 | 13.2 ± 25.94 | 9.1 ± 22.33 | 4.5 ± 29.34 |
| Body Image: Change at LTE Week 48 | 11.6 ± 25.39 | 14.9 ± 25.10 | 7.5 ± 28.45 |
| Body Image: Change at Week 72 | 11.0 ± 19.15 | 8.5 ± 16.34 | 13.8 ± 29.79 |
| Body Image: Change at LTE Week 96 | 27.1 ± 32.79 | 13.4 ± 21.87 | 10.5 ± 38.19 |
| Fatigue: Baseline (Core study Day 1) | 53.4 ± 26.83 | 55.6 ± 27.82 | 56.8 ± 29.00 |
| Fatigue: Change at LTE Day 1 | 9.3 ± 21.47 | 5.9 ± 21.05 | 7.0 ± 20.93 |
| Fatigue: Change at LTE Week 24 | 10.6 ± 23.77 | 7.1 ± 20.89 | 8.2 ± 21.96 |
| Fatigue: Change at LTE Week 48 | 7.1 ± 23.28 | 11.9 ± 22.05 | 10.8 ± 20.05 |
| Fatigue: Change at LTE Week 72 | 6.7 ± 25.98 | 2.7 ± 20.55 | 14.7 ± 30.63 |
| Fatigue: Change at LTE Week 96 | 21.1 ± 33.73 | 2.7 ± 23.09 | 20.2 ± 21.06 |
The PGIC is self-rated scale that asks the participant to describe the change in activity limitations, symptoms, emotions, and overall Quality of life (QoL) related to the participant's painful condition on the following scale: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) and 7 (very much worse). Number of participants in the PGIC categories of very much improved (1) and much improved (2) are reported.
| Participants | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| LTE Day 1: Very much improved | 13 | 19 | 25 |
| LTE Day 1: Much improved | 29 | 33 | 27 |
| LTE Week 24: Very much improved | 18 | 22 | 22 |
| LTE Week 24: Much improved | 35 | 29 | 40 |
| LTE Week 48: Very much improved | 16 | 20 | 24 |
| LTE Week 48: Much improved | 26 | 24 | 30 |
| LTE Week 72: Very much improved | 7 | 10 | 10 |
| LTE Week 72: Much improved | 13 | 13 | 13 |
| LTE Week 96: Very much improved | 4 | 2 | 7 |
| LTE Week 96: Much improved | 4 | 7 | 5 |
EQ-5D questionnaire comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels; 1=no problem, 2=moderate problems, 3=extreme problems. This part, called the EQ-5D descriptive system, provides a 5-dimensional description of health status. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. Baseline was defined as Day 1 of Core study.
| Units on a scale | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Baseline (Core Study Day 1) | 0.736 ± 0.1707 | 0.775 ± 0.1754 | 0.751 ± 0.2388 |
| Change at LTE Day 1 | 0.038 ± 0.1764 | 0.042 ± 0.1759 | 0.070 ± 0.1912 |
| Change at LTE Week 24 | 0.078 ± 0.1651 | 0.024 ± 0.2207 | 0.072 ± 0.1933 |
| Change at LTE Week 48 | 0.065 ± 0.2050 | 0.045 ± 0.2393 | 0.076 ± 0.2414 |
| Change at LTE Week 72 | 0.045 ± 0.1531 | 0.000 ± 0.2126 | 0.087 ± 0.2609 |
| Change at LTE Week 96 | 0.138 ± 0.1257 | -0.015 ± 0.1767 | 0.132 ± 0.1927 |
EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Baseline defined as Day 1 of core study.
| mm | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Baseline (Core Study Day 1) | 61 ± 18.8 | 65 ± 21.4 | 65 ± 22.2 |
| Change at LTE Day 1 | 9 ± 16.0 | 11 ± 21.5 | 8 ± 18.1 |
| Change at LTE Week 24 | 13 ± 19.7 | 12 ± 21.4 | 11 ± 18.4 |
| Change at LTE Week 48 | 15 ± 18.4 | 14 ± 23.9 | 9 ± 19.6 |
| Change at LTE Week 72 | 12 ± 18.9 | 12 ± 19.6 | 10 ± 18.1 |
| Change at LTE Week 96 | 19 ± 17.6 | 12 ± 20.9 | 10 ± 21.6 |
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status.
| Units on a scale | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Baseline; Day 1 (Core Study) | 29 ± 10.1 | 32 ± 13.1 | 31 ± 13.1 |
| Change at LTE Day 1 | 4 ± 9.5 | 4 ± 10.2 | 4 ± 9.8 |
| Change at LTE Week 24 | 5 ± 10.1 | 3 ± 10.9 | 4 ± 9.9 |
| Change at LTE Week 48 | 5 ± 11.2 | 4 ± 12.3 | 5 ± 9.9 |
| Change at LTE Week 72 | 4 ± 11.3 | 2 ± 10.2 | 6 ± 10.2 |
| Change at LTE Week 96 | 13 ± 15.5 | 3 ± 8.4 | 9 ± 9.2 |
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. Treatment-Emergent adverse events (TEAEs) are defined as events with an onset date on or after the date of first dose of study treatment in the core study and ongoing at LTE study entry, or occurring during LTE study.
| Participants | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Number of Participants With at Least One Adverse Event | 68 | 67 | 76 |
The C-SSRS assesses the suicidal behavior and suicidal ideation in participants. Occurrence of suicidal behavior after study entry is defined as having answered "yes" to a least 1 of the 4 suicidal behavior subcategories (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Occurrence of suicidal ideation is defined as having answered "yes" to at least 1 of the suicidal ideation sub-categories (1) wish to be dead, (2) nonspecific active suicidal thoughts, (3) active suicidal ideation with any methods (no plan) without intent to act, (4) active suicidal ideation with some intent to act (without specific plan), and (5) active suicidal ideation with specific plan and intent).
| Participants | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Occurrence of Suicidal Behavior at LTE Day 1 | 0 | 0 | 0 |
| Occurrence of Suicidal Behavior at LTE Week 24 | 0 | 0 | 0 |
| Occurrence of Suicidal Behavior at LTE Week 48 | 0 | 0 | 0 |
| Occurrence of Suicidal Behavior at LTE Week 72 | 0 | 0 | 0 |
| Occurrence of Suicidal Behavior at LTE Week 96 | 0 | 0 | 0 |
| Occurrence of Suicidal Ideation at LTE Day 1 | 0 | 0 | 0 |
| Occurrence of Suicidal Ideation at LTE Week 24 | 0 | 0 | 0 |
| Occurrence of Suicidal Ideation at LTE Week 48 | 0 | 0 | 0 |
| Occurrence of Suicidal Ideation at LTE Week 72 | 1 | 0 | 1 |
| Occurrence of Suicidal Ideation at LTE Week 96 | 0 | 1 | 0 |
Collected over Baseline up to maximum duration of 167.7 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/Atacicept 150 mg | 0/83 (0%) | 19/83 (22.9%) | 65/83 (78.3%) |
| Atacicept 75 mg | 0/82 (0%) | 13/82 (15.9%) | 65/82 (79.3%) |
| Atacicept 150 mg | 2/88 (2.3%) | 11/88 (12.5%) | 75/88 (85.2%) |
| Event | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| PneumoniaInfections and infestations | 2/83 | 2/82 | 1/88 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 0/83 | 2/82 | 1/88 |
| Herpes zosterInfections and infestations | 2/83 | 0/82 | 0/88 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/83 | 0/82 | 2/88 |
| Meniere's diseaseEar and labyrinth disorders | 0/83 | 1/82 | 0/88 |
| GastritisGastrointestinal disorders | 0/83 | 1/82 | 1/88 |
| Soft tissue infectionInfections and infestations | 0/83 | 1/82 | 0/88 |
| Animal biteInjury, poisoning and procedural complications | 0/83 | 1/82 | 0/88 |
| Radius fractureInjury, poisoning and procedural complications | 0/83 | 1/82 | 0/88 |
| HypocalcaemiaMetabolism and nutrition disorders | 0/83 | 1/82 | 1/88 |
| Event | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|
| Injection site reactionGeneral disorders | 23/83 | 14/82 | 22/88 |
| Urinary tract infectionInfections and infestations | 18/83 | 14/82 | 17/88 |
| Upper respiratory tract infectionInfections and infestations | 7/83 | 11/82 | 15/88 |
| Injection site painGeneral disorders | 11/83 | 4/82 | 14/88 |
| HeadacheNervous system disorders | 11/83 | 3/82 | 10/88 |
| BronchitisInfections and infestations | 7/83 | 10/82 | 2/88 |
| NasopharyngitisInfections and infestations | 8/83 | 8/82 | 5/88 |
| SinusitisInfections and infestations | 3/83 | 7/82 | 5/88 |
| Back painMusculoskeletal and connective tissue disorders | 3/83 | 7/82 | 4/88 |
| PharyngitisInfections and infestations | 3/83 | 6/82 | 6/88 |
Modified intent-to-treat (mITT) analysis set: defined as all enrolled participants in the LTE study. Efficacy analyses were performed on the mITT analysis set according to randomized treatment.
| Age, Continuous(Years) | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg | Total |
|---|---|---|---|---|
| Mean | 41 ± 13.0 | 37 ± 10.7 | 38 ± 11.5 | 39 ± 11.8 |
| Sex: Female, Male(Participants) | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg | Total |
|---|---|---|---|---|
| Female | 74 | 75 | 82 | 231 |
| Male | 9 | 7 | 6 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 48 | 43 | 40 | 131 |
| Not Hispanic or Latino | 35 | 39 | 48 | 122 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo/Atacicept 150 mg | Atacicept 75 mg | Atacicept 150 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 3 | 3 | 10 |
| Asian | 7 | 13 | 13 | 33 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 3 | 3 | 7 | 13 |
| White | 64 | 58 | 55 | 177 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 5 | 10 | 19 |
Ran from Jul 2014 to primary completion in Apr 2016, 20 months.
Results were first posted in Mar 2019, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein
Lupus Erythematosus, Systemic →